Abstract
Background: The sirolimus-eluting stent (SES) and the paclitaxel-eluting stent (PES) reduce restenosis in small coronary artery lesions. However, it is not clear which of these stents is superior in terms of clinical outcomes. Methods: The authors retrospectively examined 197 patients with 245 de novo small coronary artery lesions (≤2.75 mm) that were treated with either the SES (156 lesions) or the PES (89 lesions). Six-month angiographic restenosis rates and the 9-month target lesion revascularization (TLR) rates were compared between the two groups. Results: In terms of baseline clinical and angiographic parameters, the two groups well matched together. Six-month angiographie follow-up was performed on 170 patients (86.3%), comprising 135 SES lesions (86.5%) and 76 PES lesions (85.4%). At 6-month angiographic follow-up, the late lumen loss was less in the SES group than in the PES group (0.29 ± 0.42 vs. 0.69 ± 0.63 mm, P < 0.01). Therefore, the SES group showed a lower rate of angiographic restenosis than the PES group (6.7% vs. 27.7%, P < 0.01). At 9 months there were no deaths or myocardial infarctions in either group. The 9-month TLR rate was lower in the SES group than in the PES group (3.3% vs. 14.4%, P < 0.01). The Kaplan-Meier estimate of freedom from TLR at 9 months was 96.7% for the SES patients and 86.5% for the PES patients (P < 0.01). Conclusions: The SES treatment may be superior to the PES treatment in terms of long-term clinical and angiographic outcomes in patients with small coronary artery lesions.
| Original language | English |
|---|---|
| Pages (from-to) | 589-594 |
| Number of pages | 6 |
| Journal | Catheterization and Cardiovascular Interventions |
| Volume | 67 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2006 Apr 1 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Radiology Nuclear Medicine and imaging
- Cardiology and Cardiovascular Medicine
Cite this
}
Comparison of the effectiveness of sirolimus- and paclitaxel-eluting stents for small coronary artery lesions. / Park, Kyoung Ha; Park, Seong Wook; Hong, Myeongki; Kim, Young Hak; Lee, Bong Ki; Park, Duk Woo; Choi, Bong Ryong; Kim, Mi Jeong; Park, Kyoung Min; Lee, Cheol Whan; Cheong, Sang Sig; Kim, Jae Joong; Park, Seung Jung.
In: Catheterization and Cardiovascular Interventions, Vol. 67, No. 4, 01.04.2006, p. 589-594.Research output: Contribution to journal › Article
TY - JOUR
T1 - Comparison of the effectiveness of sirolimus- and paclitaxel-eluting stents for small coronary artery lesions
AU - Park, Kyoung Ha
AU - Park, Seong Wook
AU - Hong, Myeongki
AU - Kim, Young Hak
AU - Lee, Bong Ki
AU - Park, Duk Woo
AU - Choi, Bong Ryong
AU - Kim, Mi Jeong
AU - Park, Kyoung Min
AU - Lee, Cheol Whan
AU - Cheong, Sang Sig
AU - Kim, Jae Joong
AU - Park, Seung Jung
PY - 2006/4/1
Y1 - 2006/4/1
N2 - Background: The sirolimus-eluting stent (SES) and the paclitaxel-eluting stent (PES) reduce restenosis in small coronary artery lesions. However, it is not clear which of these stents is superior in terms of clinical outcomes. Methods: The authors retrospectively examined 197 patients with 245 de novo small coronary artery lesions (≤2.75 mm) that were treated with either the SES (156 lesions) or the PES (89 lesions). Six-month angiographic restenosis rates and the 9-month target lesion revascularization (TLR) rates were compared between the two groups. Results: In terms of baseline clinical and angiographic parameters, the two groups well matched together. Six-month angiographie follow-up was performed on 170 patients (86.3%), comprising 135 SES lesions (86.5%) and 76 PES lesions (85.4%). At 6-month angiographic follow-up, the late lumen loss was less in the SES group than in the PES group (0.29 ± 0.42 vs. 0.69 ± 0.63 mm, P < 0.01). Therefore, the SES group showed a lower rate of angiographic restenosis than the PES group (6.7% vs. 27.7%, P < 0.01). At 9 months there were no deaths or myocardial infarctions in either group. The 9-month TLR rate was lower in the SES group than in the PES group (3.3% vs. 14.4%, P < 0.01). The Kaplan-Meier estimate of freedom from TLR at 9 months was 96.7% for the SES patients and 86.5% for the PES patients (P < 0.01). Conclusions: The SES treatment may be superior to the PES treatment in terms of long-term clinical and angiographic outcomes in patients with small coronary artery lesions.
AB - Background: The sirolimus-eluting stent (SES) and the paclitaxel-eluting stent (PES) reduce restenosis in small coronary artery lesions. However, it is not clear which of these stents is superior in terms of clinical outcomes. Methods: The authors retrospectively examined 197 patients with 245 de novo small coronary artery lesions (≤2.75 mm) that were treated with either the SES (156 lesions) or the PES (89 lesions). Six-month angiographic restenosis rates and the 9-month target lesion revascularization (TLR) rates were compared between the two groups. Results: In terms of baseline clinical and angiographic parameters, the two groups well matched together. Six-month angiographie follow-up was performed on 170 patients (86.3%), comprising 135 SES lesions (86.5%) and 76 PES lesions (85.4%). At 6-month angiographic follow-up, the late lumen loss was less in the SES group than in the PES group (0.29 ± 0.42 vs. 0.69 ± 0.63 mm, P < 0.01). Therefore, the SES group showed a lower rate of angiographic restenosis than the PES group (6.7% vs. 27.7%, P < 0.01). At 9 months there were no deaths or myocardial infarctions in either group. The 9-month TLR rate was lower in the SES group than in the PES group (3.3% vs. 14.4%, P < 0.01). The Kaplan-Meier estimate of freedom from TLR at 9 months was 96.7% for the SES patients and 86.5% for the PES patients (P < 0.01). Conclusions: The SES treatment may be superior to the PES treatment in terms of long-term clinical and angiographic outcomes in patients with small coronary artery lesions.
UR - http://www.scopus.com/inward/record.url?scp=33646037329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646037329&partnerID=8YFLogxK
U2 - 10.1002/ccd.20700
DO - 10.1002/ccd.20700
M3 - Article
VL - 67
SP - 589
EP - 594
JO - Catheterization and Cardiovascular Interventions
JF - Catheterization and Cardiovascular Interventions
SN - 1522-1946
IS - 4
ER -